ABOUT PURGO
Advancing science to deliver the next generation of biomaterials for lasting bone and tissue regeneration.
Rebuilding bone, maintaining volume over time, and providing the biological foundation essential for long-term implant stability are at the heart of what we do. Our goal is simple but ambitious: to promote the formation of vital, well-vascularized bone that remains stable and functional for years to come.
Our research is guided by a deep understanding of the biological processes behind bone regeneration. We design biomaterials that work in harmony with the body’s natural healing mechanisms supporting angiogenesis, bone formation, and physiological remodeling. We do not simply fill defects; we aim to regenerate living, functional tissue.
This approach is strengthened through close collaborations with clinicians, researchers, and leading academic institutions worldwide. Together, we ensure that our solutions are scientifically sound, clinically relevant, and truly beneficial for patients.
By combining continuous innovation with uncompromising quality standards, we advance the field of tissue regeneration and provide clinicians with solutions they can trust every day.
OUR VISION
Supporting patients through every step, from diagnosis to bone regeneration, with innovative biological solutions.
OUR MISSION
Advance osteoimmunology research and develop biomaterials that help the immune system restore dental tissues.
OUR VALUES
Excellence, technology, regeneration, science, biomimetics and innovation.
Purgo Biologics has endeavored to contribute from the development of global dental treatment and clinical science to the improvement of human oral health by continuously supplying products through scientific and structured processes over the past 20 years to clinical professionals around the world.
PURGO BIOLOGICS MILESTONES
1999
FOUNDATION
Established Purgo Biologics.
2000
FOUNDATION
Concluded domestic supply contract with ACE Surgical Supply (USA).
2001
FOUNDATION
Concluded domestic supply contract with Hartzell and Son (USA).
2002
FOUNDATION
Signed a distributor contract with Rocky Mountain Tissue Bank (USA).
2003
FOUNDATION
Signed an exclusive distributor contract in Asia of Biomatlante (France).
Released sales of Happylon®.
2005
FOUNDATION
Established Purgo Tissue Bank.
Released domestic sales of suture of Shirakawa (Japan).
2010
BONE & MEMBRANE SPECIALIZATION
Established Purgo R&D Center (Pangyo).
2011
BONE & MEMBRANE SPECIALIZATION
Obtained certificate of Manufacturer of Medical Devices from Korean MFDS.
2012
BONE & MEMBRANE SPECIALIZATION
Received certificate of Registration of Quality Management System ISO 13485:2016.
2012
BONE & MEMBRANE SPECIALIZATION
Obtained CE certificate of OpenTex.
Obtained KGMP (Korea Good Manufacturing Practice) Korean MFDS certificate.
2013
BONE & MEMBRANE SPECIALIZATION
THE Graft was approved as a manufacturer item by Korean MFDS.
Obtained TFDA (Taiwan) certificate of OpenTex.
2013
BONE & MEMBRANE SPECIALIZATION
Obtained CMDCAS certificate of OpenTex.
Concluded domestic supply contract of resorbable collagen membrane. Authorized as a venture company.
2014
Global Growth
Biotex was approved as a manufacturer item by the Korean MFDA.
2015
FOUNDATION
OpenTex-TR was approved as a manufactured item by Korean MFDA.
Obtained TFDA (Taiwan) & CE certificate of THE Graft, concluded global sales contract of THE Graft in 18 EU countries.
2016
Global Growth
The factory and laboratory were relocated to cover global supply, a randomized clinical trial lecture of THE Graft was published in SCI journal.
2017
Global Growth
Obtained CE certificate of THE Graft, OpenTex, OpenTex-TR and BioTex.
Obtained health Canada certificate of THE Graft, OpenTex, OpenTex-TR and BioTex.
2017
Global Growth
Obtained Roszdravnadzor (Russia) certificate of THE Graft, OpenTex, OpenTex-TR and BioTex.
Concluded supply contract in Portugal, Spain & Canada.
Selected as a specialist company in human resources development.
2018
To the next level
Obtained MDSAP certificate (ISO 13485:2016).
Obtained FDA, CDSCO certificate of THE Graft, obtained ANVISA (Brazil) certificate of Biotex.
Selected as Frontier Export Company.
2019
To the next level
Obtained certificate of THE Graft in Ukraine.
Obtained FDA (USA) certificate of Biotex.
Obtained NMPA (CFDA) certificate of THE Graft.
2020
To the next level
Built up the “Strategic Cooperative Partnership” with CareCapital.
2021
To the next level
Purgo HQ moved to Pangyo Technovalley.
Purgo Europe Branch opening as Europe Importer.
2022
To the next level
Obtained TFDA (Taiwan) certificate THE Graft Collagen;
Obtained MFDS (Korea) certificate THE Cover;
Purgo Europe expands distribution in 20 countries.
2023
To the next level
Obtained Health Canada (Canada) certificate of THE Cover;
Obtained MFDS (Korea) certificate of BCP Graft Collagen;
Obtained GOST (Russia) certificate of THE Graft Collagen;
2023
To the next level
Obtained FDA (USA) certificate of OpenTex;
Obtained FDA (USA) certificate of THE Cover;
Launch of RegenDays Congress in Europe;
FDA Clearance of Opentex and THECover.
2024
To the next level
Obtained ANVISA (Brazil) certificate of THE Cover;
Obtained TFDA (Taiwan) certificate;
Obtained FDA (US) certificate of THE Graft Collagen;
Obtained KGMP (Korea Manufacturing Pratice) certificate.
2024
To the next level
Launch of RegenClass in Europe;
Research collaboration Francfurt Univ.;
CE Mark THE Cover Flex & Stiff.
2025
To the next level
Obtainer CDSCO (India) certificate of THE Graft Collagen;
Obtainer GOST (Russia) certificate of THE Cover;
Open Purgo Germany, UK and Benelux;
Open Purgo US branch;
QUALITY MANAGEMENT
KTR-ABBA-7058 (GMP)
Manage all the processes with a quality system designed to manufacture safe and effective products.
Control and assess quality with the latest analytical instrument.
EN ISO 13485:2016 (NSAI)
Establish a quality management system following quality control standards.
Manage relevant documents based on international standards.
Assess the quality of products by performing tests and analysis.
Updates and internal audits are regularly performed for preventative measures.
Assess the conformity of quality management with KGMP, ISO, MDSAP.
DMSAP ISO13485:2016 (NSAI)
Comply with the laws and regulations of countries.
Continuously improve quality and innovate.
Contribute to growth by continuously delivering customer satisfaction.
CORPORATE IDENTITY
20 years, we have drawn inspiration from the principles of biology and the natural processes of living tissues to create safe and effective regenerative products.
We have come to see that humans, as part of nature, exist in harmony with these biological systems. By following the lessons of biology, we translate our knowledge and insights into products that respect natural cycles, reflecting the wisdom and balance inherent in life itself.
Insights from dental regenerative trials have taught us that achieving outstanding results relies as much on the quality of materials as on the skill of the procedure.
At Purgo, we create nature-inspired, user-friendly solutions that work in harmony with the body’s own biological processes, allowing clinicians to achieve predictable and consistent results.
Ease of use is more than a detail, it lies at the heart of clinical efficiency and successful outcomes. Achieving reliable results depends not only on the skill of the clinician or their knowledge of materials, but also on the ability to choose the right solution for each situation with confidence and precision.
At Purgo, our expertise goes beyond supplying biomaterials: we guide clinicians in their use, case by case, to unlock the full potential of each solution. To deliver predictable and lasting results, we offer a broad range of tailored solutions, built on reliable and proven products designed in harmony with the natural laws of regeneration.